Another clinical trial, NCT05989347, is a single-arm Phase I study that examines whether dapagliflozin, administered in conjunction with standard neoadjuvant therapies, can favorably alter metabolic markers of insulin resistance in women with early-stage HER2- breast cancer. Here, ERBB2 is linked to breast carcinoma.